Patent · US Active

Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers

US11866500B2 · kind B2 · utility

1Cited by
1References
17Claims
0Family size

Assignees

Inventors

Key dates

Filing dateNov 12, 2021
Grant dateJan 9, 2024
Priority date
Expiry dateNov 12, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/565
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.